Harnessing innate immunity to suppress lymphoma.
Stevenson
Freda K
FK
Johnson
Peter W M
PW
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D006801:Humans; D007113:Immunity, Innate; D008223:Lymphoma / Q000276:immunology*; D051379:Mice; D009838:Oligodeoxyribonucleotides / Q000276:immunology*; D012074:Remission Induction; D051217:Toll-Like Receptor 9 / Q000819:agonists* / Q000276:immunology*
C408982:CPG-oligonucleotide; D019496:Cancer Vaccines; D009838:Oligodeoxyribonucleotides; C495371:TLR9 protein, human; D051217:Toll-Like Receptor 9